The Zhitong Finance App learned that Genting Xinyao B (01952) had a high of nearly 5% in early trading. As of press release, it had risen 2.11% to HK$31.5, with a turnover of HK$49.5448 million.

According to the news, on October 30, Genting Xinyao announced that the latest analysis results of the NepGard study with Nafucan (budesonide enteric capsule, NEFECON) will be announced at the 2024 American Nephrology Association Kidney Week (ASN Kidney Week 2024). The results showed that Tolfukang can specifically regulate the production of GALT pathogenic IgA (GD-IgA1) without altering systemic IgA response and total serum immunoglobulin (Ig) levels. At the same time, compared to other B-cell therapies currently being developed for IgA nephropathy, Tolerecan has no inhibitory effect on the whole body's humoral immune system, selectively reducing GD-IgA1 while maintaining overall serum total immunoglobulin levels.

In addition, complete Chinese subgroup data from the complete 2-year NepGard Phase III study was recently published in the world's top nephrology journal “Kidney 360” (Kidney 360). At the level of commercialization, in addition to being approved in Macau, mainland China, Hong Kong, and Singapore, Nafukang has also recently been approved in Taiwan, China, and is expected to obtain approval for the marketing of new drugs in South Korea before the end of the year. According to financial data, since Naifukang first issued prescriptions in mainland China in May 2024, product sales revenue reached 0.1673 billion yuan just over a month after launch.